A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease

Trial Profile

A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Triheptanoin (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TRIHEP3
  • Most Recent Events

    • 08 Mar 2017 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
    • 15 Dec 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 10 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top